What Do Published Case Reports Reveal About Ozempic and Gastroparesis?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Awareness to Targeted Drug Safety

If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may wonder whether the medication could be causing a condition called gastroparesis. Medical case reports have documented instances where these symptoms emerged during treatment and improved after stopping the drug. Building on decades of pharmacovigilance research, this page reviews published case series to help you understand the reported patterns and what they mean for your health.

Bridging General Knowledge to Specific Risk: Ozempic and Gastroparesis

Building on the foundation of general health awareness, we now focus on the specific question of whether Ozempic (semaglutide) can cause gastroparesis. Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Its mechanism involves slowing gastric emptying, which contributes to glycemic control but also raises concerns about gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, and abdominal pain. Clinical presentation of gastroparesis overlaps with common gastrointestinal adverse effects reported in Ozempic trials. In placebo-controlled studies, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (1.9% placebo, 3.5% 0.5 mg, 2.7% 1 mg), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms mirror those of gastroparesis, though the label does not explicitly list gastroparesis as a reported adverse reaction.

Mechanistic Evidence: How Ozempic May Cause Gastroparesis

Mechanistically, GLP-1 receptor agonists like Ozempic delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone, which can exacerbate or unmask gastroparesis in susceptible individuals. The pharmacologic slowing of gastric motility is dose-dependent, as evidenced by higher gastrointestinal adverse reaction rates at the 2 mg dose compared to 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This effect is typically most pronounced during dose initiation and escalation, aligning with the observation that the majority of nausea, vomiting, and diarrhea reports occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, for some patients, delayed gastric emptying may persist, leading to chronic gastroparesis-like symptoms even after dose stabilization. Risk considerations center on the adequacy of warnings. The Ozempic label does not include a specific warning for gastroparesis, though it notes gastrointestinal adverse reactions and advises caution in patients with a history of pancreatitis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This omission may leave patients and clinicians unaware of the potential for gastroparesis, particularly in those with pre-existing gastric motility disorders or diabetes-related autonomic neuropathy, which itself increases gastroparesis risk.

Causation Considerations and Clinical Implications

For affected patients, causation considerations require evaluating the temporal relationship between Ozempic initiation and symptom onset. The label indicates that gastrointestinal reactions are most common during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), suggesting a plausible timeline of weeks to months after starting therapy or increasing dose. However, symptoms may also emerge later, complicating attribution. Discontinuation of Ozempic often leads to symptom resolution, supporting a causal link, but persistent cases may require further diagnostic evaluation, such as gastric emptying studies, to confirm gastroparesis. The timeline between exposure and documented harm is variable. In clinical trials, gastrointestinal adverse reactions leading to discontinuation occurred at rates of 3.1% for 0.5 mg and 3.8% for 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), indicating that a subset of patients experienced intolerable symptoms early in treatment. For those who develop gastroparesis, harm may be documented through diagnostic tests or persistent symptoms affecting quality of life. The absence of a specific gastroparesis warning in the label (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166) may delay recognition and management, increasing risk of complications such as malnutrition, dehydration, or bezoar formation. In summary, while Ozempic’s label documents gastrointestinal adverse reactions that overlap with gastroparesis symptoms, it does not explicitly warn of gastroparesis as a potential adverse effect. The mechanistic link through delayed gastric emptying, combined with dose-dependent gastrointestinal reaction rates and timing during dose escalation, supports a plausible causation pathway. Affected patients should be monitored for persistent gastrointestinal symptoms, and clinicians should consider gastroparesis in the differential diagnosis, especially when symptoms are severe or lead to treatment discontinuation. Improved labeling and patient education could enhance risk communication and early intervention.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) slows gastric emptying as part of its mechanism, which can cause or worsen gastroparesis—a condition of delayed stomach emptying. Clinical trials show higher rates of gastrointestinal adverse reactions like nausea and vomiting, which overlap with gastroparesis symptoms. The label does not explicitly warn of gastroparesis, but the mechanistic and clinical evidence supports a plausible causal link.

How common is gastroparesis with Ozempic use?

Exact rates are not specified, but gastrointestinal adverse reactions leading to discontinuation occurred in 3.1% (0.5 mg) and 3.8% (1 mg) of patients in trials (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Many of these symptoms may represent gastroparesis, though the label does not list it separately.

What should I do if I experience gastroparesis symptoms while taking Ozempic?

Consult your healthcare provider immediately. Symptoms like persistent nausea, vomiting, early satiety, or abdominal pain may indicate gastroparesis. Your doctor may recommend diagnostic tests (e.g., gastric emptying study) and consider adjusting or discontinuing Ozempic.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.